Literature DB >> 9293448

Good engraftment of B-cell precursor ALL in NOD-SCID mice.

G Baersch1, T Möllers, A Hötte, B Dockhorn-Dworniczak, C Rübe, J Ritter, H Jürgens, J Vormoor.   

Abstract

BACKGROUND: In vivo models for human B cell precursor ALL have been established by transplanting human leukemic cells onto immune-deficient SCID mice. High risk and relapsed leukemias engraft very well in these mice, however, good prognosis pediatric ALL often grow poorly if at all. Recently a new, even more immune-deficient mouse strain has been bred by crossing the scid mutation onto the NOD mouse background. As these NOD-SCID mice have been shown to be better recipients for human myeloid cells the goal of this study was to test these mice as hosts for human acute lymphoblastic leukemia cells. PATIENTS AND METHODS: Bone marrow or peripheral blood cells from/pediatric and one adult patient with B-cell precursor ALL were transplanted onto immune-deficient NOD-SCID mice according to established protocols. MAIN
RESULTS: ALL cells from 6 out of the 8 patients (75%) successfully engrafted the NOD-SCID mice and from 4 patients (50%) led to an extensive leukemic infiltration in the murine marrow (> 10%). High level human cell engraftment could be demonstrated by flow cytometry, Southern blot analysis and cytology. By cytology and immunophenotype the leukemia in the mice was indistinguishable from the original leukemia in the patients. The presence of few human eosinophils in the marrow of highly engrafted mice indicates minimal coengraftment of residual normal cells. Development of overt leukemia in the mice after transplantation of cells from different patients varied between 1.5 and 7 months. Interestingly and in contrast to myeloid cells, conditioning of the mice by sublethal irradiation was not necessary for successful engraftment. Limiting dilution experiments with leukemic blasts from one patient showed that as few as 10000 cells were sufficient to transfer the leukemia onto NOD-SCID mice.
CONCLUSIONS: NOD-SCID mice are sensitive recipients for human ALL xenografts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293448     DOI: 10.1055/s-2008-1043947

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  20 in total

Review 1.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

2.  Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).

Authors:  Susan J Zunino; David H Storms; Jonathan M Ducore
Journal:  Cancer Lett       Date:  2010-04-09       Impact factor: 8.679

3.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Authors:  David M Barrett; Alix E Seif; Carmine Carpenito; David T Teachey; Jonathan D Fish; Carl H June; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

4.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

Authors:  David T Teachey; Dana A Obzut; Jonathan Cooperman; Junjie Fang; Martin Carroll; John K Choi; Peter J Houghton; Valerie I Brown; Stephan A Grupp
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

5.  A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.

Authors:  Reshmi Parameswaran; Markus Müschen; Yong-Mi Kim; John Groffen; Nora Heisterkamp
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

6.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

7.  Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.

Authors:  Amy L Samuels; Violet K Peeva; Rachael A Papa; Marin J Firth; Richard W Francis; Alex H Beesley; Richard B Lock; Ursula R Kees
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

8.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

Authors:  Christoph le Viseur; Marc Hotfilder; Simon Bomken; Kerrie Wilson; Silja Röttgers; André Schrauder; Annegret Rosemann; Julie Irving; Ronald W Stam; Leonard D Shultz; Jochen Harbott; Heribert Jürgens; Martin Schrappe; Rob Pieters; Josef Vormoor
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

Review 9.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology.

Authors:  Bella Patel; Aditi Dey; Anna Z Castleton; Claire Schwab; Edward Samuel; Janani Sivakumaran; Brendan Beaton; Nahid Zareian; Christie Yu Zhang; Lena Rai; Tariq Enver; Anthony V Moorman; Adele K Fielding
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.